ASSOCIATION OF MATERNAL TDF-BASED ART WITH BONE MINERAL CONTENT IN BREASTFEEDING INFANTS

Tichaona Vhembo1, Kristin Baltrusaitis2, Camlin Tierney3, Maxensia Owor4, Sufia Dadabho5, AvyVic6, Gerhard Theron7, Dhayendra Moodley7, Cynthia Mukwasi-Kaham8, Kathleen George9, John Shepherd10, George K. Silbern11

1University of Zimbabwe Clinical Trials Research Centre, Harare, Zimbabwe, 2Harvard TH Chan School of Public Health, Boston, MA, United States, 3MUJHU, Kampala, Uganda, 4Johns Hopkins Bloomberg School of Public Health, Blantyre, Malawi, 5PRNU, University of the Western Cape, South Africa, 6CAPRISA and University of KwaZulu Natal, Durban, South Africa, 7University of Zimbabwe Faculty of Medicine and Health Sciences, Harare, Zimbabwe, 8NHI, Surhanh, NC, United States, 9University of Hawaii Cancer Centre, Honolulu, HI, 10USA United States Agency for International Development, Washington, DC, United States, 11National Institute of Allergy and Infectious Diseases, Bethesda, MD, United States, 12The Johns Hopkins University School of Medicine, Baltimore, MD, United States, 13University of Zimbabwe Faculty of Medicine and Health Sciences / UZ-CTRC, Harare, Zimbabwe.

BACKGROUND

• Tenovir disoproxil fumarate (TDF) is an important agent for antiretroviral treatment (ART) and prevention of HIV in breastfeeding women, but information about the impact of postpartum use on infant bone and renal safety is limited.

• The IMPAACT PROMISE P1084s substudy [NCT01066858] assessed these outcomes in a subset of mother-infant pairs randomized to either maternal TDF-based ART [TDF/FTC+LPV/r] (mART) or infant nevirapine prophylaxis [no maternal ART] (iNVP) during breastfeeding.

METHODS

• Healthy pairs with normal maternal renal function and no antenatal exposure to maternal TDF who were randomized in PROMISE 1:1 to mART or INVP at 6-14 days postpartum were eligible for the P1084s substudy.

• Most pairs were enrolled in P1084s on randomization day and followed through Week 74.

• Infant lumbar spine bone mineral content (LS-BMC) was assessed at entry and Week 26 by dual energy x-ray absorptiometry, read centrally by blinded investigators.

• Infant creatinine clearance (CrCl) was calculated using the revised Schwartz equation at entry and Weeks 10, 26, and 74.

• Student t-tests compared mean LS-BMC and CrCl at Week 26 and mean change from entry between arms. All differences are presented as mART – INVP.

RESULTS

• 400 pairs were enrolled; 2 mART pairs excluded because the mothers did not initiate TDF-based ART.

• At entry [Figure 1], mean (standard deviation (sd)) infant LS-BMC was 1.68g (0.35) and CrCl was 64.2mL/min per 1.73 m² (24.6).

• At Week 26, 98% pairs were breastfeeding and 96% were on their assigned antiretroviral strategy.

• Mean (sd) Week 26 LS-BMC was 2.64g (0.48) for mART and 2.77g (0.44) for INVP: mean difference (95% confidence interval (CI)) -0.13g (-0.22, -0.04), P=0.007, n = 375/398 (94%) [Figure 2]. Mean absolute (-0.14g (-0.23, -0.06)) and percent change (-10.88% (-18.53, -3.23)) in LS-BMC from entry was smaller for mART than INVP. Similar results were observed in post hoc analyses of bone mineral density.

• At Week 26, mean (sd) CrCl was 130.0mL/min per 1.73 m² (34.9) for mART vs. 126.1mL/min per 1.73 m² (30.0) for INVP; mean difference (95% CI) 3.8 (-3.0, 7.7), P=0.27, n = 349/398 (88%).

CONCLUSIONS

• Although the mean LS-BMC at Week 26 was lower in breastfeeding infants with TDF containing mART compared with INVP, the difference was less than a half sd (~0.23g), thus clinical relevance is unlikely.

• No infant renal safety concerns were observed.

ACKNOWLEDGEMENTS

The IMPAACT PROMISE Protocol Team gratefully acknowledges the dedication and commitment of the 400 mother-infant pairs that participated in this substudy, their communities, and CAB representatives, without whom this study would not have been possible. The authors also wish to acknowledge the IMPAACT PROMISE Protocol team, NIAID, NICHD, and NIMH, and the four IMPACT sites and staff. The study products were provided free of charge by Abbott, Gilead Sciences, Boehringer Ingelheim, and GlaxoSmithKline.